By using cutting-edge academic expertise and technology services to de-risk and improve the translation of academic and SME-driven developments towards the patient, EATRIS enhances biomedical innovation in Europe and acts as an EU reference point where all stakeholders involved in the translational medicine value chain can work together.
Flagship efforts fostering innovation are the IMI projects EU-Pearl and EPND, the GlaxoSmithKline Imaging Hub, conceptualised and managed by EATRIS, and the REMEDi4ALL repurposing project driving the future of drug repurposing in Europe.
Additional efforts include the recent inception of EATRIS Expert Centres, providing crucial but scarce knowledge to advance the development plan of translational projects – supporting innovation. These services cover a range of areas, such as innovation management, regulatory strategy, translational feasibility, and early health technology assessment.
To evidence EATRIS’ contribution to fostering innovation, we track key performance indicators that reflect how EATRIS supports translational projects through specialised expertise and research services. In 2025, EATRIS supported 9 projects through innovation management, regulatory, and HTA support, and performed 11 research services, contributing to the advancement of innovative translational developments. Since 2018, this has amounted to 65 projects supported and since 2014 altogether 116 research services delivered, demonstrating sustained contribution to strengthening biomedical innovation across Europe.
Examples of our work in this area:
Swedish biotech UmanDiagnostics finds new collaborators through EATRIS support
UmanDiagnostics, a leader in neurological disease diagnostics, shares how a presentation in Umeå sparked a valuable collaboration journey through EATRIS.
Providing a unique setting for patient-centric, academically driven research complemented with industry strengths
Glaxosmithkline (GSK) Imaging hub, conceptualised and managed by EATRIS for GSK (large pharma) delivers a clinical and scientific expert network for the development and application of innovative imaging methods for inflammatory diseases. The long-term collaboration between GSK and 6 EATRIS institutions represents more than €4m of financing from GSK to our institutions.
EATRIS Expertise in Action: Supporting Heptammune’s Clinical Development Pathway
EATRIS offers a multitude of expert services to our members, including Regulatory advice. Here is feedback from EATRIS member Bellvitge Biomedical Research Institute (IDIBELL) from a recent service provided by one of EATRIS experts in Regulatory Science.
European flagship driving the drug repurposing future of Europe
REMEDi4ALL, an ambitious EU-funded research initiative, coordinated by EATRIS launched in 2022 to drive forward the repurposing of medicines in Europe (23M euros, 24 partners).
Expert Centres advancing translational projects through providing crucial knowledge
EATRIS Expert Services are crucial components of a comprehensive development plan for translational projects. These services cover a range of areas, such as innovation management, regulatory strategy, translational feasibility, and early health technology assessment. They complement the existing laboratory research services in EATRIS institutions, and also aim to further support national competence building.
Concluding the Journey of the EATRIS-GSK Imaging Hub
The GlaxoSmithKline (GSK) Translational Molecular Imaging Hub, a pioneering public-private partnership developed by EATRIS and GSK, will soon be concluding. Since its inception in 2018, this collaborative imaging Hub has united scientific and clinical experts to advance innovative imaging methods for inflammatory diseases, achieving progress in translating research findings into clinical applications.
